Matthew Nugent

Professor and Dean


Contact Info

Science Complex, Room 4203


Postdoc, Chemical Engineering, Massachusetts Institute of Technology,
Harvard-MIT Health Sciences and Technology

Ph.D., Biochemistry, Brandeis University

B.A., Biochemistry, Brandeis University

Areas of Expertise

Cell biology and biochemistry

Extracellular matrix

Growth factors


Vascular biology


Dr. Nugent has been actively engaged in research on extracellular matrix and growth factors with a particular interest in heparan sulfate proteoglycan biology and biochemistry. His group applies an interdisciplinary combination of biochemical, cell biology, molecular, biophysical and computational approaches to generate a systems biology understanding of growth factor regulation of cell function.

His work has led to several discoveries and has contributed to the current understanding of heparan sulfate structure and function in various normal and disease states including: cancer, cardiovascular disease and emphysema. He has served as principal investigator on over 20 research grants (~$20M), most of which have been from the National Institutes of Health including a large program project grant to study the mechanism of lung injury. His research has led to more than 110 peer-reviewed publications, 5 book chapters, 8 patents (assigned/published) and more than 200 invited lectures and published abstracts. His published work has been cited over 8,500 times with an h-index of 56.

Dr. Nugent serves/served as editor and member of the editorial boards of several scientific journals, and as a reviewer and chair on multiple NIH, NSF and private foundation grant review panels. He has also served as a consultant for 20 biotechnology and pharmaceutical companies.


For a full list, visit Dr. Nugent’s Google Scholar Publication list.

Nugent, M.A. The Future of the COVID-19 Pandemic: How Good (or Bad) can the SARS-CoV2 Spike Protein Get? (2022) Cells 11, 855. 

Tsiros, D.; Sheehy, C.E.; Nugent, M.A. Heparin–Avastin Complexes Show Enhanced VEGF Binding and Inhibition of VEGF-Mediated Cell Migration. (2021) Int. J. Transl. Med. 1, 101-115. 

Zabroski, I.O., and Nugent, M.A. Lipid raft association stabilizes VEGF receptor 2 in endothelial cells. (2021) Int. J. Mol. Sci., 22, 798; 

Tsiros, D., Sheehy, C.E., Pecchia, S., and Nugent, M.A. Heparin potentiates Avastin-mediated inhibition of VEGF binding to fibronectin and rescues Avastin activity at acidic pH (2019) J. Biol. Chem. 294, 17603-17611. PMID: 31601651

Buczek-Thomas, J., Rich, C.B., and Nugent, M.A. Hypoxia induced heparan sulfate primes the extracellular matrix for endothelial cell recruitment by facilitating VEGF-fibronectin interactions. (2019) Int. J. Mol. Sci. 20, 5065. PMID: 31614727

Teran, M, and Nugent, M.A. Characterization of receptor binding kinetics for vascular endothelial growth factor-A using SPR. (2019) Analytical Biochem. 564, 21-31. PMID: 30292477